The report that a single injection of BAFFR monoclonal antibody that prevents BAFF binding drastically reduced mature B cells without affecting B1a cells [19] prompted us to explore the therapeutic potential of this monoclonal antibody to BAFFR to attenuate atherosclerosis in the hyperlipidemic ApoE−/− mouse. Here, APOE is linked to atherosclerosis.